Amunix Pharmaceuticals, Inc.
2 Tower Pl #1100
South San Francisco
About Amunix Pharmaceuticals, Inc.
At Amunix, we are focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. We are leveraging our proprietary T cell engager (XPAT(tm)) and cytokine (XPAC) platforms to advance novel prodrugs that overcome the toxicity and immunogenicity challenges common to these therapeutic modalities via selective activation in the tumor microenvironment. By delivering breakthrough therapies that can safely harness the immune system, we aim to conquer cancer and save lives.
Since our founding in 2006, we have operated as a technology licensing company, forging agreements with multiple leading biopharmaceutical companies such as Roche, Merck, Celgene, and Biogen, to leverage XTEN, a proprietary half-life extension technology, and Pro-XTEN, a next-generation prodrug technology. Pro-XTEN utilizes a protease-releasable XTEN polypeptide as a mask, thus enabling localized activation of potent therapies. This technology is designed to overcome a common challenge facing potent immune system activators: on-target, off-tumor toxicity. Pro-XTEN, which is the foundational technology for the XPAT and XPAC platforms, has been clinically validated, with the most advanced program utilizing the technology currently in a pivotal Phase 3 study for a non-oncology indication.
We are advancing our lead development candidate, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, toward the clinic, and we have several discovery programs underway.
31 articles with Amunix Pharmaceuticals, Inc.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020
Amunix Pharmaceuticals today shared new data on AMX-818 (HER2-XPAT), the company’s lead clinical candidate T cell engager which targets HER2. Data was presented at the 2020 San Antonio Breast Cancer Symposium.
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors
The 2020 virtual meeting of the European Society of Medical Oncology is getting underway and companies are lining up to share information on their latest cancer treatments.
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors Prodrug XPATs demonstrated >1000 fold increase in tolerated exposures versus traditional T cell engagers Amunix’s lead program, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, continues to progress toward the clinic MOUNTAIN VIEW, Calif., June 22, 2020 (GLOBE NEWS
Amunix Pharmaceuticals, Inc. announced the appointment of Anne Keane as the Senior Vice President of Regulatory and Quality for Amunix.
Nearly two months after inking a licensing deal worth up to $1.5 billion with Roche, Amunix Pharmaceuticals secured $73 million in an oversubscribed Series A financing round.
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing.
Amunix Pharmaceuticals, based in Mountain View, California, entered a licensing deal with Roche. Under the terms of the deal, Roche will pay Amunix $40 million upfront.
Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing pro-drugs to enable the promise of potent immune-activating biotherapeutics in solid tumors, today announced that it has provided a technology license to F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (“Roche”) to utilize Amunix’s technology platform, XTEN, to discover and develop non-oncology therapeutics against certain undisclosed targets
Amunix Announces Appointment of Dr. Angie You as Chief Executive Officer and Dr. Rich Heyman as Chairman of the Board of Directors
Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on the discovery and development of novel protein therapeutics, today announced the appointment of Angie You, Ph.D., as Chief Executive Officer, and Rich Heyman, Ph.D., as Chairman of the Board of Directors.
Amunix, Inc. Release: IND Submission To Initiate Clinical Trials Of NB 1001 (XTEN-GLP1) For Treatment Of Short Bowel Syndrome Announced By Naia Rare Diseases
Amunix, Inc. And PolyPeptide Laboratories Inc. Enter Into Partnership To Produce XTEN Peptide Conjugates For Evaluation By Third Parties For Pharmaceutical Therapeutics
Amunix, Inc. Signs A Services And Supply Agreement With The University Of Nebraska-Lincoln To Produce GMP-Grade XTEN For Pharmaceutical Therapeutics
Amunix, Inc. And PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates In Vivo Studies In American Chemical Society's Journal